USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook
Key Financial Results
Third Quarter 2025 vs. Third Quarter 2024
-
Net sales of
versus$214 million , representing$200 million 7% year-over-year growth. -
Net loss of -
versus net earnings of$6.5 million .$10.6 million -
Diluted EPS of -
as compared with$0.36 .$0.56 -
Adjusted diluted EPS(1) of -
as compared with$0.15 .$0.56 -
Adjusted EBITDA(2) of
versus$13.8 million .$24.6 million - Direct selling Active Customers of 388,000 versus 452,000.
- Hiya Active Monthly Subscribers of 193,400.
Q3 2025 Financial Performance
Consolidated Results |
|||
|
Year-Over-Year |
Sequentially |
|
Net Sales |
|
+ |
- |
Net (Loss) Earnings* |
- |
N/A |
N/A |
- |
N/A |
N/A |
|
Adjusted Diluted EPS(1) |
- |
N/A |
N/A |
Adjusted EBITDA(2) |
|
- |
- |
*Pretax earnings for Q3 2025 totaled |
|||
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of |
“USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025,” said Jim Brown, President and Chief Executive Officer. “We rolled out our enhanced Brand Partner compensation plan during the third quarter. Since this launch, our commercial team has been actively training, educating and supporting Brand Partners across our global markets to help them leverage the new plan. We are encouraged by the pickup in sales activity and leader productivity in recent weeks. Our enhanced compensation plan represents a bold and strategic move to modernize our business and better position our Brand Partners, and the Company, for long-term success in a competitive landscape.
“We held a successful Global Convention in
“Hiya, our direct-to-consumer (DTC) business, has delivered
Q3 2025 Direct Selling Regional Results:
|
|||||
|
Year-Over-Year |
Year-Over-Year
|
Sequentially |
||
Net Sales |
|
- |
- |
- |
|
Active Customers |
308,000 |
- |
N/A |
- |
Asia Pacific Sub-Regions |
|||||
|
|
Year-Over-Year |
Year-Over-Year
|
Sequentially |
|
|
Net Sales |
|
- |
No meaningful FX impact |
- |
Active |
210,000 |
- |
N/A |
- |
|
Customers |
|||||
|
Net Sales |
|
- |
- |
+ |
Active |
37,000 |
- |
N/A |
—% |
|
Customers |
|||||
|
Net Sales |
|
- |
- |
- |
Active |
61,000 |
- |
N/A |
- |
|
Customers |
|
||||
|
|
Year-Over-Year |
Year-Over-Year
|
Sequentially |
Net Sales* |
|
+ |
+ |
+ |
Active Customers |
80,000 |
- |
N/A |
- |
*Includes |
||||
Q3 2025 Hiya Direct to Consumer Results:
Hiya |
|
Net Sales |
|
Active Monthly Subscribers |
193,400 |
Balance Sheet
The Company ended the quarter with
Fiscal Year 2025 Outlook
The Company is updating its outlook for fiscal year 2025, as follows:
Fiscal Year 2025 Outlook |
||
|
Updated Estimate |
Previous Range |
Consolidated net sales |
|
|
Net earnings |
|
|
Diluted EPS |
|
|
Adjusted Diluted EPS(1) |
|
|
Adjusted EBITDA(2) |
|
|
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of |
Doug Hekking, Chief Financial Officer, commented, “Short-term profitability was burdened during the third quarter due to softer than anticipated sales, meaningful investments to support the roll out of our enhanced Brand Partner compensation plan, and a change in the estimated annual effective income tax rate that disproportionately impacted the current year quarter. Specifically, lower than expected earnings coupled with the concentration of operating and administrative expenses in
“Our revised outlook reflects modest sequential improvement in both our direct sales and DTC businesses, albeit from a lower customer base as a result of third quarter performance. We have initiated and are executing a comprehensive process to align all costs throughout the business globally with our current level of sales. As a result of this realignment and rightsizing process, we expect to incur an estimated one-time charge of
The Company’s fiscal 2025 outlook reflects:
-
Net sales from the direct selling business of approximately
;$788 million -
Net sales from Hiya of approximately
, reflecting year-over-year growth of$132 million 16% ; - Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.
____________________ |
(1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
Non-GAAP Financial Measures
This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.
Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.
Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.
Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.
The Company prepares its financial statements using
Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands) |
||||||||||||||||
|
|
Quarter Ended |
|
Nine months ended |
||||||||||||
|
|
September 27, 2025 |
|
September 28, 2024 |
|
September 27, 2025 |
|
September 28, 2024 |
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Net earnings (loss) attributable to USANA (GAAP) |
|
$ |
(6,522 |
) |
|
$ |
10,607 |
|
|
$ |
12,535 |
|
|
$ |
37,576 |
|
Net earnings (loss) attributable to noncontrolling interest |
|
|
(140 |
) |
|
|
— |
|
|
|
537 |
|
|
|
— |
|
Net earnings (loss) |
|
$ |
(6,662 |
) |
|
$ |
10,607 |
|
|
$ |
13,072 |
|
|
$ |
37,576 |
|
|
|
|
|
|
|
|
|
|
||||||||
Adjustments: |
|
|
|
|
|
|
|
|
||||||||
Income taxes |
|
$ |
8,456 |
|
|
$ |
8,001 |
|
|
$ |
24,278 |
|
|
$ |
28,346 |
|
Interest (income) expense |
|
|
(529 |
) |
|
|
(3,093 |
) |
|
|
(1,201 |
) |
|
|
(8,429 |
) |
Depreciation and amortization |
|
|
5,112 |
|
|
|
5,559 |
|
|
|
16,050 |
|
|
|
16,345 |
|
Amortization of intangible assets - Hiya |
|
|
4,455 |
|
|
|
— |
|
|
|
13,366 |
|
|
|
— |
|
Earnings before interest, taxes, depreciation, and amortization (EBITDA) |
|
$ |
10,832 |
|
|
$ |
21,074 |
|
|
$ |
65,565 |
|
|
$ |
73,838 |
|
|
|
|
|
|
|
|
|
|
||||||||
Add EBITDA adjustments: |
|
|
|
|
|
|
|
|
||||||||
Non-cash share-based compensation |
|
|
3,576 |
|
|
|
3,542 |
|
|
|
10,078 |
|
|
|
10,945 |
|
Transaction, integration and transition costs - Hiya |
|
|
179 |
|
|
|
— |
|
|
|
871 |
|
|
|
— |
|
Inventory step-up - Hiya |
|
|
— |
|
|
|
— |
|
|
|
1,126 |
|
|
|
— |
|
Consolidated adjusted EBITDA |
|
|
14,587 |
|
|
|
24,616 |
|
|
|
77,640 |
|
|
|
84,783 |
|
Less: Adjusted EBITDA attributable to noncontrolling interest |
|
|
(804 |
) |
|
|
— |
|
|
|
(3,604 |
) |
|
|
— |
|
Adjusted EBITDA attributable to USANA |
|
$ |
13,783 |
|
|
$ |
24,616 |
|
|
$ |
74,036 |
|
|
$ |
84,783 |
|
Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted (Loss) Earnings Per Share (non-GAAP) (in thousands, except per share data) |
||||||||||||||||
|
|
Quarter Ended |
|
Nine months ended |
||||||||||||
|
|
September 27, 2025 |
|
September 28, 2024 |
|
September 27, 2025 |
|
September 28, 2024 |
||||||||
Net earnings (loss) attributable to USANA (GAAP) |
|
$ |
(6,522 |
) |
|
$ |
10,607 |
|
$ |
12,535 |
|
|
$ |
37,576 |
||
|
|
|
|
|
|
|
|
|
||||||||
Earnings (loss) per common share - Diluted (GAAP) |
|
$ |
(0.36 |
) |
|
$ |
0.56 |
|
$ |
0.67 |
|
|
$ |
1.96 |
||
Weighted Average common shares outstanding - Diluted |
|
|
18,293 |
|
|
|
19,083 |
|
|
18,671 |
|
|
|
19,181 |
||
|
|
|
|
|
|
|
|
|
||||||||
Adjustment to net earnings (loss): |
|
|
|
|
|
|
|
|
||||||||
Transaction, integration and transition costs - Hiya |
|
$ |
179 |
|
|
$ |
— |
|
$ |
871 |
|
|
$ |
— |
||
Inventory step-up - Hiya |
|
|
— |
|
|
|
— |
|
|
1,126 |
|
|
|
— |
||
Amortization of intangible assets - Hiya |
|
|
4,455 |
|
|
|
— |
|
|
13,366 |
|
|
|
— |
||
Adjustments to net earnings (loss) attributable to noncontrolling interest |
|
|
(941 |
) |
|
|
— |
|
|
(3,066 |
) |
|
|
— |
||
Income tax effect of adjustments to net earnings (loss) |
|
|
— |
|
|
|
— |
|
|
(4 |
) |
|
|
— |
||
Adjusted net earnings (loss) attributable to USANA |
|
$ |
(2,829 |
) |
|
$ |
10,607 |
|
$ |
24,828 |
|
|
$ |
37,576 |
||
|
|
|
|
|
|
|
|
|
||||||||
Adjusted earnings (loss) per common share - Diluted |
|
$ |
(0.15 |
) |
|
$ |
0.56 |
|
$ |
1.33 |
|
|
$ |
1.96 |
||
Weighted average common shares outstanding - Diluted |
|
|
18,293 |
|
|
|
19,083 |
|
|
18,671 |
|
|
|
19,181 |
||
Management Commentary Document and Conference Call
For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Thursday, October 23, 2025 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “expect,” “enhance,” “drive,” “anticipate,” “intend,” “improve,” “promote,” “should,” “believe,” “continue,” “plan,” “goal,” “opportunity,” “estimate,” “predict,” “may,” “will,” “could,” and “would,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding Hiya’s growth in 2025 and continued growth in the future; statements about the Company’s long-term growth; and the statements under the sub-heading “Fiscal Year 2025 Outlook.” Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in
About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) |
||||||||
|
Three Months Ended |
|
||||||
|
September 27,
|
|
September 28,
|
|
||||
Net sales |
$ |
213,670 |
|
|
$ |
200,221 |
|
|
Cost of sales |
|
48,815 |
|
|
|
39,257 |
|
|
Gross profit |
|
164,855 |
|
|
|
160,964 |
|
|
Operating expenses: |
|
|
|
|
||||
Brand Partner incentives |
|
77,684 |
|
|
|
84,068 |
|
|
Selling, general and administrative |
|
85,947 |
|
|
|
61,295 |
|
|
Total operating expenses |
|
163,631 |
|
|
|
145,363 |
|
|
Earnings from operations |
|
1,224 |
|
|
|
15,601 |
|
|
Other income (expense): |
|
|
|
|
||||
Interest income |
|
578 |
|
|
|
3,142 |
|
|
Interest expense |
|
(49 |
) |
|
|
(49 |
) |
|
Other, net |
|
41 |
|
|
|
(86 |
) |
|
Other income (expense), net |
|
570 |
|
|
|
3,007 |
|
|
Earnings before income taxes |
|
1,794 |
|
|
|
18,608 |
|
|
Income taxes |
|
8,456 |
|
|
|
8,001 |
|
|
Net (loss) earnings |
|
(6,662 |
) |
|
|
10,607 |
|
|
Less: Net (loss) earnings attributable to redeemable noncontrolling interest |
|
(140 |
) |
|
|
— |
|
|
Net (loss) earnings attributable to USANA |
$ |
(6,522 |
) |
|
$ |
10,607 |
|
|
|
|
|
|
|
||||
(Loss) earnings per common share attributable to USANA |
|
|
|
|
||||
Basic |
$ |
(0.36 |
) |
|
$ |
0.56 |
|
|
Diluted |
$ |
(0.36 |
) |
|
$ |
0.56 |
|
|
|
|
|
|
|
||||
Weighted average common shares outstanding |
|
|
|
|
||||
Basic |
|
18,293 |
|
|
|
19,078 |
|
|
Diluted |
|
18,293 |
|
|
|
19,083 |
|
|
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) |
||||||||
|
As of
|
|
As of
|
|||||
ASSETS |
|
|
|
|||||
Current assets |
|
|
|
|||||
Cash and cash equivalents |
$ |
145,349 |
|
$ |
181,768 |
|||
Inventories |
|
90,781 |
|
|
69,735 |
|||
Prepaid expenses and other current assets |
|
27,935 |
|
|
27,684 |
|||
Total current assets |
|
264,065 |
|
|
279,187 |
|||
Property and equipment, net |
|
96,212 |
|
|
94,565 |
|||
Goodwill |
|
144,288 |
|
|
144,168 |
|||
Intangible assets, net |
|
138,159 |
|
|
151,823 |
|||
Deferred tax assets |
|
24,157 |
|
|
19,644 |
|||
Other assets* |
|
59,710 |
|
|
58,806 |
|||
Total assets |
$ |
726,591 |
|
$ |
748,193 |
|||
|
|
|
|
|||||
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY |
|
|
|
|||||
Current liabilities |
|
|
|
|||||
Accounts payable |
$ |
17,095 |
|
$ |
11,984 |
|||
Line of credit |
|
— |
|
|
23,000 |
|||
Other current liabilities |
|
101,569 |
|
|
104,641 |
|||
Total current liabilities |
|
118,664 |
|
|
139,625 |
|||
Deferred tax liabilities |
|
4,467 |
|
|
4,073 |
|||
Other long-term liabilities |
|
21,907 |
|
|
18,163 |
|||
|
|
|
|
|||||
Redeemable noncontrolling interest |
|
53,479 |
|
|
54,223 |
|||
|
|
|
|
|||||
Total stockholders' equity attributable to USANA |
|
528,074 |
|
|
532,109 |
|||
Total liabilities, redeemable noncontrolling interest, and stockholders' equity |
$ |
726,591 |
|
$ |
748,193 |
|||
*Includes noncurrent inventories of |
||||||||
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES SALES BY REGION (in thousands) (unaudited) |
||||||||||||||||||||||||||
|
Quarter Ended |
|
|
|
|
|||||||||||||||||||||
|
September 27,
|
|
September 28,
|
|
Change from
|
|
Percent
|
|
Currency impact
|
|
Percent
|
|||||||||||||||
Direct Selling: |
|
|
|
|
|
|
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||
|
$ |
92,571 |
43.3 |
% |
$ |
102,261 |
51.1 |
% |
$ |
(9,690 |
) |
(9.5 |
%) |
$ |
504 |
|
(10.0 |
%) |
||||||||
|
|
29,178 |
13.7 |
% |
|
37,267 |
18.6 |
% |
|
(8,089 |
) |
(21.7 |
%) |
|
393 |
|
(22.8 |
%) |
||||||||
|
|
17,690 |
8.3 |
% |
|
20,541 |
10.2 |
% |
|
(2,851 |
) |
(13.9 |
%) |
|
(403 |
) |
(11.9 |
%) |
||||||||
|
|
139,439 |
65.3 |
% |
|
160,069 |
79.9 |
% |
|
(20,630 |
) |
(12.9 |
%) |
|
494 |
|
(13.2 |
%) |
||||||||
|
|
36,386 |
17.0 |
% |
|
38,398 |
19.2 |
% |
|
(2,012 |
) |
(5.2 |
%) |
|
72 |
|
(5.4 |
%) |
||||||||
Direct Selling total |
|
175,825 |
82.3 |
% |
|
198,467 |
99.1 |
% |
|
(22,642 |
) |
(11.4 |
%) |
|
566 |
|
(11.7 |
%) |
||||||||
Hiya |
|
30,846 |
14.4 |
% |
|
— |
— |
% |
|
30,846 |
|
N/A |
|
|
— |
|
N/A |
|
||||||||
Other |
|
6,999 |
3.3 |
% |
|
1,754 |
0.9 |
% |
|
5,245 |
|
299.0 |
% |
|
— |
|
299.0 |
% |
||||||||
Consolidated total |
$ |
213,670 |
100.0 |
% |
$ |
200,221 |
100.0 |
% |
$ |
13,449 |
|
6.7 |
% |
$ |
566 |
|
6.4 |
% |
||||||||
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES DIRECT SELLING ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION (unaudited) |
||||||||
Direct Selling Active Brand Partners by Region(1) |
||||||||
|
(unaudited) | |||||||
|
|
As of
|
|
As of
|
||||
|
|
|
|
|
|
|
|
|
|
|
61,000 |
|
36.3 % |
|
65,000 |
|
34.6 % |
|
|
43,000 |
|
25.6 % |
|
52,000 |
|
27.6 % |
|
|
27,000 |
|
16.1 % |
|
28,000 |
|
14.9 % |
Asia Pacific Total |
|
131,000 |
|
78.0 % |
|
145,000 |
|
77.1 % |
|
|
|
|
|
|
|
|
|
|
|
37,000 |
|
22.0 % |
|
43,000 |
|
22.9 % |
|
|
168,000 |
|
100.0 % |
|
188,000 |
|
100.0 % |
Direct Selling Active Preferred Customers by Region(2) |
||||||||
|
(unaudited) |
|||||||
|
|
As of
|
|
As of
|
||||
|
|
|
|
|
|
|
|
|
|
|
149,000 |
|
67.7 % |
|
178,000 |
|
67.4 % |
|
|
18,000 |
|
8.2 % |
|
24,000 |
|
9.1 % |
|
|
10,000 |
|
4.6 % |
|
13,000 |
|
4.9 % |
Asia Pacific Total |
|
177,000 |
|
80.5 % |
|
215,000 |
|
81.4 % |
|
|
|
|
|
|
|
|
|
|
|
43,000 |
|
19.5 % |
|
49,000 |
|
18.6 % |
|
|
220,000 |
|
100.0 % |
|
264,000 |
|
100.0 % |
______________________________ |
|
(1) |
Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale. |
(2) |
Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. |
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES OPERATING RESULTS AS A PERCENTAGE OF NET SALES (unaudited) |
||||||||||||
|
|
Quarter Ended |
||||||||||
|
|
September 27, 2025 |
|
September 28, 2024 |
||||||||
|
|
Direct selling & Other |
|
Hiya direct-to-consumer |
|
Consolidated |
|
Direct selling & Other |
|
Hiya direct-to-consumer |
|
Consolidated |
Net sales |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Cost of sales |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Gross profit |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Brand Partner incentives |
|
|
|
—% |
|
|
|
|
|
N/A |
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Total operating expenses |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Earnings (loss) from operations |
|
|
|
(2.1)% |
|
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets |
|
|
|
|
|
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended |
||||||||||
|
|
September 27, 2025 |
|
September 28, 2024 |
||||||||
|
|
Direct selling & Other |
|
Hiya direct-to-consumer |
|
Consolidated |
|
Direct selling & Other |
|
Hiya direct-to-consumer |
|
Consolidated |
Net sales |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Cost of sales |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Gross profit |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Brand Partner incentives |
|
|
|
—% |
|
|
|
|
|
N/A |
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Total operating expenses |
|
|
|
|
|
|
|
|
|
N/A |
|
|
Earnings from operations |
|
|
|
|
|
|
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets |
|
|
|
|
|
|
|
|
|
N/A |
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20251022419409/en/
Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com
Media contact:
Sarah Searle
(801) 954-7626
media@usanainc.com
Source: USANA Health Sciences, Inc.